Abstract
An estimated 17.6 per 100,000 new cases of childhood cancer are diagnosed each year in the United States. The major subtypes of childhood cancer include leukemia, central nervous system tumors, lymphoma, neuroblastoma, rhabdomyosarcoma, osteosarcoma, Ewing sarcoma, Wilms tumor, Germ cell tumors, and other rare tumors. Despite improvements in the diagnosis and treatment of these tumors over the last 30 years, subsets of children still have poor outcomes and many others have significant morbidity. Dysregulation of apoptotic pathways has been shown to contribute to tumor formation as well as resistance to therapy in both pediatric and adult malignancies. Survivin, the smallest member of the inhibitor of apoptosis protein (IAP) family, is highly expressed in diverse cancers and correlates with decreased patient survival. Here, we review the current literature on Survivin expression in pediatric cancer, its relationship to clinical outcome and potential therapeutic options to target this protein in pediatric cancer.
Keywords: Apoptosis, IAP, pediatric cancer, surviving, CNS tumor, caspase, Lymphoma, dysregulation, cytoplasm, Nucleus
Current Pediatric Reviews
Title: Inhibition of Apoptosis in Pediatric Cancer by Survivin
Volume: 7 Issue: 4
Author(s): Ayman Samkari and Rachel A. Altura
Affiliation:
Keywords: Apoptosis, IAP, pediatric cancer, surviving, CNS tumor, caspase, Lymphoma, dysregulation, cytoplasm, Nucleus
Abstract: An estimated 17.6 per 100,000 new cases of childhood cancer are diagnosed each year in the United States. The major subtypes of childhood cancer include leukemia, central nervous system tumors, lymphoma, neuroblastoma, rhabdomyosarcoma, osteosarcoma, Ewing sarcoma, Wilms tumor, Germ cell tumors, and other rare tumors. Despite improvements in the diagnosis and treatment of these tumors over the last 30 years, subsets of children still have poor outcomes and many others have significant morbidity. Dysregulation of apoptotic pathways has been shown to contribute to tumor formation as well as resistance to therapy in both pediatric and adult malignancies. Survivin, the smallest member of the inhibitor of apoptosis protein (IAP) family, is highly expressed in diverse cancers and correlates with decreased patient survival. Here, we review the current literature on Survivin expression in pediatric cancer, its relationship to clinical outcome and potential therapeutic options to target this protein in pediatric cancer.
Export Options
About this article
Cite this article as:
Samkari Ayman and A. Altura Rachel, Inhibition of Apoptosis in Pediatric Cancer by Survivin, Current Pediatric Reviews 2011; 7 (4) . https://dx.doi.org/10.2174/157339611796892283
DOI https://dx.doi.org/10.2174/157339611796892283 |
Print ISSN 1573-3963 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6336 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
How Immune-inflammatory Processes Link CNS and Psychiatric Disorders: Classification and Treatment Implications
CNS & Neurological Disorders - Drug Targets Does in vitro Fertilisation Increase Type 2 Diabetes and Cardiovascular Risk?
Current Diabetes Reviews Drug Delivery Systems for the Treatment of Diabetes Mellitus: State of the Art
Current Pharmaceutical Design Effect of an Angiotensin II Receptor Blocker and Two Angiotensin Converting Enzyme Inhibitors on Transforming Growth Factor-β (TGF-β) and α-Actomyosin (α SMA), Important Mediators of Radiation-Induced Pneumopathy and Lung Fibrosis
Current Pharmaceutical Design The Potential and Limitations of p38MAPK as a Drug Target for the Treatment of Hematological Malignancies
Current Drug Targets Cancer Vaccines: Emphasis on Pediatric Cancers
Current Pharmaceutical Design Cannabis and Psychosis: A Systematic Review of Genetic Studies
Current Psychiatry Reviews Current Options and Perspectives in the Treatment of Diabetic Neuropathy
Current Pharmaceutical Design Multidrug Resistance: Retrospect and Prospects in Anti-Cancer Drug Treatment
Current Medicinal Chemistry Epigenetic Modifications in Acute Lymphoblastic Leukemia: From Cellular Mechanisms to Therapeutics
Current Gene Therapy Cancer Pharmacogenomics: Germline DNA, Tumor DNA, or Both?
Current Pharmacogenomics Main Nutritional and Environmental Risk Factors in Children with Leukemia from a Public Hospital of the State of Guanajuato, Mexico
Current Cancer Therapy Reviews Phage Display Derived Therapeutic Antibodies
Current Pharmaceutical Biotechnology The Stress-Vulnerability Model of Schizophrenia: A Conceptual Analysis and Selective Review
Current Psychiatry Reviews Oncogenic Fusion Tyrosine Kinases as Molecular Targets for Anti-Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Obesity: An Emerging Importance of Progenitors
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Predicted Contributions of Flavin-containing Monooxygenases to the N-oxygenation of Drug Candidates Based on their Estimated Base Dissociation Constants
Current Drug Metabolism Pathogenesis, Experimental Models and Contemporary Pharmacotherapy of Irritable Bowel Syndrome: Story About the Brain-Gut Axis
Current Neuropharmacology A Conceptual View on Glucocorticoid-Induced Apoptosis, Cell Cycle Arrest and Glucocorticoid Resistance in Lymphoblastic Leukemia
Current Molecular Medicine Methylglyoxal, A Metabolite Increased in Diabetes is Associated with Insulin Resistance, Vascular Dysfunction and Neuropathies
Current Drug Metabolism